EP1178810B8 - Use of bisphosphonic acids for treating angiogenesis - Google Patents

Use of bisphosphonic acids for treating angiogenesis Download PDF

Info

Publication number
EP1178810B8
EP1178810B8 EP00936760A EP00936760A EP1178810B8 EP 1178810 B8 EP1178810 B8 EP 1178810B8 EP 00936760 A EP00936760 A EP 00936760A EP 00936760 A EP00936760 A EP 00936760A EP 1178810 B8 EP1178810 B8 EP 1178810B8
Authority
EP
European Patent Office
Prior art keywords
patient
bisphosphonic acids
treating angiogenesis
treatment
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
EP00936760A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1178810B1 (en
EP1178810A2 (en
Inventor
Tetsuji Okuno
Jonathan Green
Jeanette Marjorie Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1178810(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9911926.5A external-priority patent/GB9911926D0/en
Priority claimed from GBGB9925131.6A external-priority patent/GB9925131D0/en
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Priority to SI200030701T priority Critical patent/SI1178810T1/xx
Publication of EP1178810A2 publication Critical patent/EP1178810A2/en
Publication of EP1178810B1 publication Critical patent/EP1178810B1/en
Application granted granted Critical
Publication of EP1178810B8 publication Critical patent/EP1178810B8/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00936760A 1999-05-21 2000-05-19 Use of bisphosphonic acids for treating angiogenesis Revoked EP1178810B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI200030701T SI1178810T1 (en) 1999-05-21 2000-05-19 Use of bisphosphonic acids for treating angiogenesis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9911926.5A GB9911926D0 (en) 1999-05-21 1999-05-21 Organic compounds
GB9911926 1999-05-21
GB9925131 1999-10-22
GBGB9925131.6A GB9925131D0 (en) 1999-10-22 1999-10-22 Organic compounds
PCT/EP2000/004562 WO2000071104A2 (en) 1999-05-21 2000-05-19 Use of bisphosphonic acids for treating angiogenesis

Publications (3)

Publication Number Publication Date
EP1178810A2 EP1178810A2 (en) 2002-02-13
EP1178810B1 EP1178810B1 (en) 2005-04-20
EP1178810B8 true EP1178810B8 (en) 2005-07-27

Family

ID=26315578

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00936760A Revoked EP1178810B8 (en) 1999-05-21 2000-05-19 Use of bisphosphonic acids for treating angiogenesis

Country Status (21)

Country Link
US (2) US20020142996A1 (enExample)
EP (1) EP1178810B8 (enExample)
JP (1) JP2003500352A (enExample)
KR (1) KR100763064B1 (enExample)
CN (1) CN1202828C (enExample)
AT (1) ATE293450T1 (enExample)
AU (1) AU775079B2 (enExample)
BR (1) BR0010808A (enExample)
CA (1) CA2374049A1 (enExample)
DE (1) DE60019580T2 (enExample)
DK (1) DK1178810T3 (enExample)
ES (1) ES2240106T3 (enExample)
HU (1) HUP0201329A3 (enExample)
IL (2) IL146520A0 (enExample)
NO (1) NO322212B1 (enExample)
NZ (1) NZ515541A (enExample)
PL (1) PL351674A1 (enExample)
PT (1) PT1178810E (enExample)
SK (1) SK16682001A3 (enExample)
TW (1) TWI224504B (enExample)
WO (1) WO2000071104A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287278B6 (sk) * 2000-06-20 2010-05-07 Novartis Ag Použitie kyseliny 1-hydroxy-2-(imidazol-1-yl)etán-1,1- difosfónovej na prípravu liečiva na liečenie stavov abnormálne zvýšeného kostného obratu
SI1591122T1 (sl) * 2000-06-20 2013-02-28 Novartis Ag Postopek za aplikacijo bisfosfonatov
CN1233325C (zh) * 2001-02-06 2005-12-28 罗亚尔·亚历山德拉儿童医院 治疗骨坏死和处理有发展为骨坏死危险的患者用的药物
RU2297229C2 (ru) * 2001-05-02 2007-04-20 Новартис Аг Фармацевтическое применение бисфосфонатов
ES2336312T3 (es) * 2001-07-16 2010-04-12 Universite Paris 13 Procedimiento de preparacion de derivados de bisfosfonatos.
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
CA2763775C (en) 2002-05-10 2014-01-07 F. Hoffmann-La Roche Ag Bisphosphonic acids for the treatment and prevention of osteoporosis
DE60233576D1 (de) * 2002-12-02 2009-10-15 Innate Pharma Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen
WO2005014006A1 (en) * 2003-07-21 2005-02-17 Novartis Ag Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
EP1723157B2 (en) † 2004-02-26 2017-02-08 Zentiva, k.s. Amorphous forms of risedronate monosodium
KR20070043043A (ko) * 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
US7914810B2 (en) 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
EP2255199A1 (en) * 2008-02-19 2010-12-01 Jovesis Inc. Microparticle compositions to modify cancer promoting cells
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2015018659A1 (en) * 2013-08-05 2015-02-12 Vib Vzw Glutamine synthetase inhibitors for inhibition of pathological angiogenesis
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
DE3425812A1 (de) * 1984-07-13 1986-01-16 Deutsches Krebsforschungszentrum, 6900 Heidelberg Neue 1-hydroxy-1,1-diphosphonsaeureverbindungen, verfahren zu ihrer herstellung und pharmakologische zubereitungen, insbesondere zur behandlung von knochentumoren
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
SE9402001D0 (sv) * 1994-06-09 1994-06-09 Leiras Oy Pyridylbisphosphonates for use as a therapeutical agent
IT1290444B1 (it) * 1997-03-27 1998-12-03 Boehringer Mannheim Italia Coniugati di bis-fosfonati con funzionalita' alchilanti aventi attivita' antitumorale
ES2269014T3 (es) * 1997-07-22 2007-05-01 MERCK & CO. INC. Procedimiento para inhibir la resorcion osea.
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
WO1999033473A1 (fr) * 1997-12-25 1999-07-08 Toray Industries, Inc. Remedes contre les maladies intramedullaires
WO1999038998A1 (en) * 1998-01-29 1999-08-05 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
US6416964B2 (en) * 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance

Also Published As

Publication number Publication date
US20040176327A1 (en) 2004-09-09
CA2374049A1 (en) 2000-11-30
DE60019580D1 (de) 2005-05-25
WO2000071104A2 (en) 2000-11-30
EP1178810B1 (en) 2005-04-20
IL146520A0 (en) 2002-07-25
CN1384749A (zh) 2002-12-11
AU5214100A (en) 2000-12-12
EP1178810A2 (en) 2002-02-13
NZ515541A (en) 2003-03-28
HUP0201329A2 (en) 2002-08-28
DE60019580T2 (de) 2006-03-09
IL146520A (en) 2006-09-05
KR100763064B1 (ko) 2007-10-04
NO20015638D0 (no) 2001-11-19
TWI224504B (en) 2004-12-01
ES2240106T3 (es) 2005-10-16
US20020142996A1 (en) 2002-10-03
BR0010808A (pt) 2002-08-27
DK1178810T3 (da) 2005-07-11
JP2003500352A (ja) 2003-01-07
WO2000071104A3 (en) 2001-07-19
HUP0201329A3 (en) 2005-02-28
PT1178810E (pt) 2005-08-31
AU775079B2 (en) 2004-07-15
NO20015638L (no) 2002-01-15
ATE293450T1 (de) 2005-05-15
CN1202828C (zh) 2005-05-25
SK16682001A3 (sk) 2002-04-04
PL351674A1 (en) 2003-05-19
KR20010113830A (ko) 2001-12-28
NO322212B1 (no) 2006-08-28

Similar Documents

Publication Publication Date Title
EP1178810B8 (en) Use of bisphosphonic acids for treating angiogenesis
IL155363A0 (en) Use of bisphosphonates for pain treatment
CY1106482T1 (el) Φαρμακευτικη παρεντepικη συνθεση πepιεχοντας ενα διφωσφονικο
IL153229A0 (en) Method of administering bisphosphonates
RU2003133773A (ru) Фармацевтическое применение бисфосфонатов
DK0756484T3 (da) Vådgranuleringsformulering til diphosphonsyrer
Saad Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone
CA2409930A1 (en) Use of zoledronate for the manufacture of a medicament for the treatment of bone metabolism diseases
IL133172A (en) Diphosphonic acid salts for the treatment of osteoporosis
TH51552A (th) การใช้กรดบิสฟอสโฟนิคสำหรับการบำบัดแอนจิโอจีนีซิส

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011117

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI PAYMENT 20011117

17Q First examination report despatched

Effective date: 20020304

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS AG

Owner name: NOVARTIS PHARMA GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS PHARMA GMBH

Owner name: NOVARTIS AG

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60019580

Country of ref document: DE

Date of ref document: 20050525

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: NOVARTIS PHARMA GMBH

Owner name: NOVARTIS AG

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20050402203

Country of ref document: GR

Ref country code: PT

Ref legal event code: SC4A

Effective date: 20050707

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: NOVARTIS AG

Effective date: 20050713

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2240106

Country of ref document: ES

Kind code of ref document: T3

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: F.HOFFMANN-LA ROCHE AG

Effective date: 20060117

ET Fr: translation filed
NLR1 Nl: opposition has been filed with the epo

Opponent name: F.HOFFMANN-LA ROCHE AG

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20070426

Year of fee payment: 8

Ref country code: MC

Payment date: 20070426

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20070503

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20070508

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20070511

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20070514

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20070516

Year of fee payment: 8

Ref country code: PT

Payment date: 20070516

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20070517

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20070530

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20070621

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20070516

Year of fee payment: 8

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20070711

Year of fee payment: 8

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

27W Patent revoked

Effective date: 20071107

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Effective date: 20071107

REG Reference to a national code

Ref country code: PT

Ref legal event code: MP4A

Effective date: 20080416

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20070510

Year of fee payment: 8

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20070412

Year of fee payment: 8

NLR2 Nl: decision of opposition

Effective date: 20071107

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20080515

Year of fee payment: 9

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20080527

Year of fee payment: 9

Ref country code: FI

Payment date: 20080515

Year of fee payment: 9

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20100115